U Agrawal, S Bedston, C McCowan, J Oke, L Patterson… - The Lancet, 2022 - thelancet.com
Background Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups …
A Sheikh, J McMenamin, B Taylor, C Robertson - The Lancet, 2021 - thelancet.com
On May 19, 2021, the Delta Variant of Concern (VOC), formerly known as the Indian VOC or B 1.617. 2, became the dominant strain of SARS-CoV-2 in Scotland. The Alpha VOC …
A Sheikh, S Kerr, M Woolhouse… - The Lancet Infectious …, 2022 - thelancet.com
Background Since its emergence in November, 2021, in southern Africa, the SARS-CoV-2 omicron variant of concern (VOC) has rapidly spread across the world. We aimed to …
Obesity is associated with an increased risk of severe Coronavirus Disease 2019 (COVID- 19) infection and mortality. COVID-19 vaccines reduce the risk of serious COVID-19 …
A Sheikh, C Robertson, B Taylor - New England Journal of …, 2021 - Mass Medical Soc
Vaccine Efficacy against the Delta Variant in Scotland An analysis of mortality among more than 114,000 SARS-CoV-2–infected people in Scotland revealed that vaccine effectiveness …
A Sheikh, S Kerr, M Woolhouse… - The Lancet Infectious …, 2022 - thelancet.com
The Lancet family of journals publishes the latest COVID-19 related content across epidemiology, treatments, vaccines and much more. Here you can explore COVID-19 …
C Temple, R Hoang… - New England Journal of …, 2021 - Mass Medical Soc
Toxic Effects from Ivermectin Use The Oregon Poison Center received calls at a rate of 0.25 per month in all of 2020, as compared with 21 calls in August 2021 alone, regarding toxic …
SJ Stock, E Moore, C Calvert, J Carruthers… - The Lancet …, 2022 - thelancet.com
Background Evidence suggests that the SARS-CoV-2 omicron (B. 1· 1.529) is associated with lower risks of adverse outcomes than the delta (B. 1.617. 2) variant among the general …
PTV Florentino, T Millington… - The Lancet Infectious …, 2022 - thelancet.com
Background Little is known about vaccine effectiveness over time among adolescents, especially against the SARS-CoV-2 omicron (B. 1.1. 529) variant. This study assessed the …